Results for tag: "Base Editing"

In biotechnology, the Base Editing market encompasses the tools, services, and research activities related to the technology of base editing, which is a form of genome editing. Unlike broader methods such as CRISPR-Cas9, which induce double-strand breaks to create knockouts or insert new DNA sequences, base editing allows for the direct, irreversible conversion of one DNA base into another, without inducing double-strand breaks, thereby potentially reducing unintended edits or insertions. This precision technology can be applied in therapeutic settings, agriculture biotechnology, and research that requires single-nucleotide polymorphism. The market includes the development and sale of base editing components like engineered nucleases and guide RNA constructs, licensing of technologies, and the provision of services such as custom base editing and consulting. Companies and academic institutions in this field continuously engage in collaboration and intellectual property agreements to advance the technology and expand its application spectrum. Prominent participants in the base editing market include Beam Therapeutics, which specializes in developing precision genetic medicines using base editing, and CRISPR Therapeutics, which engages in gene-based treatments, including those involving novel gene-editing approaches. Other notable entities are Intellia Therapeutics and Editas Medicine, which are invested in the therapeutic application of genome editing technologies. These companies represent key innovators and market leaders, driving forward the applications and capabilities of base editing within the biotechnology sector. Show Less Read more